» Articles » PMID: 35804982

Tensin2 Is a Novel Diagnostic Marker in GIST, Associated with Gastric Location and Non-Metastatic Tumors

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Jul 9
PMID 35804982
Authors
Affiliations
Soon will be listed here.
Abstract

GIST is a rare soft tissue sarcoma, for which KIT and DOG1 are used as highly sensitive diagnostic markers. Other diagnostic markers include CD34, protein kinase C θ, deficiency of succinate dehydrogenase complex subunit B, carbonic anhydrase II, and type I insulin-like growth factor receptor. We investigated the role of TNS2 as a diagnostic biomarker by using immunohistochemistry in 176 GISTs and 521 other sarcomas. All GISTs expressed TNS2, with intermediate or high expression in 71.4% of samples. The majority (89.8%) of other sarcomas were negative for TNS2, and intermediate to strong staining was only seen in 2.9% of samples. Strong TNS2 staining was associated with gastric location (gastric 52.8% vs. non-gastric 7.2%; p < 0.001), absence of metastases (non-metastatic tumors 44.3% vs. metastatic tumors 5.9%; p = 0.004), female sex (female 45.9% vs. male 33.8%; p = 0.029), and tumors of lower risk categories (very low or low 46.9% vs. intermediate 51.7% vs. high 29.0%; p = 0.020). TNS2 expression did not correlate with overall survival or metastasis-free survival. No associations between TNS2 expression and KIT/PDGFRA mutation status, tumor size, mitotic count, or age of the patient were detected. The results provide conclusive evidence for the value of TNS2 as a sensitive and specific diagnostic biomarker for GIST.

Citing Articles

Pharmacokinetic profile and anticancer efficacy of anagrelide administered subcutaneously in rodents.

Toivanen K, Sutter L, Wozniak A, Wyns K, Merikoski N, Salmikangas S Drug Deliv. 2025; 32(1):2463433.

PMID: 39930717 PMC: 11816618. DOI: 10.1080/10717544.2025.2463433.


Is a Highly Expressed Therapy Target in Myxoid Liposarcoma.

Toivanen K, Kilpinen S, Ojala K, Merikoski N, Salmikangas S, Sampo M Cancers (Basel). 2023; 15(22).

PMID: 38001568 PMC: 10669966. DOI: 10.3390/cancers15225308.


A performance evaluation of drug response prediction models for individual drugs.

Park A, Lee Y, Nam S Sci Rep. 2023; 13(1):11911.

PMID: 37488424 PMC: 10366128. DOI: 10.1038/s41598-023-39179-2.


The molecular and clinical role of Tensin 1/2/3 in cancer.

Mainsiouw L, Ryan M, Hafizi S, Fleming J J Cell Mol Med. 2023; 27(13):1763-1774.

PMID: 37296531 PMC: 10315744. DOI: 10.1111/jcmm.17714.


Special Issue: Diagnostic and Predictive Tissue Markers in G.I. Cancers.

Chillotti S, Vasuri F Cancers (Basel). 2023; 15(4).

PMID: 36831671 PMC: 9953972. DOI: 10.3390/cancers15041329.

References
1.
Tu Y, Zuo R, Ni N, Eilers G, Wu D, Pei Y . Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression. Cell Cycle. 2018; 17(23):2577-2592. PMC: 6300111. DOI: 10.1080/15384101.2018.1553335. View

2.
Parkkila S, Lasota J, Fletcher J, Ou W, Kivela A, Nuorva K . Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol. 2010; 23(5):743-50. PMC: 2900582. DOI: 10.1038/modpathol.2009.189. View

3.
Lo S, Janmey P, Hartwig J, Chen L . Interactions of tensin with actin and identification of its three distinct actin-binding domains. J Cell Biol. 1994; 125(5):1067-75. PMC: 2120063. DOI: 10.1083/jcb.125.5.1067. View

4.
Doyle L, Nelson D, Heinrich M, Corless C, Hornick J . Loss of succinate dehydrogenase subunit B (SDHB) expression is limited to a distinctive subset of gastric wild-type gastrointestinal stromal tumours: a comprehensive genotype-phenotype correlation study. Histopathology. 2012; 61(5):801-9. DOI: 10.1111/j.1365-2559.2012.04300.x. View

5.
Lasota J, Dansonka-Mieszkowska A, Sobin L, Miettinen M . A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest. 2004; 84(7):874-83. DOI: 10.1038/labinvest.3700122. View